With the extra time today, I studied the results from the phase 3 study slides. Well, having been an excellent students of statistics, the results really impressed me. Even after Tobi raced out of the gate with a comfortable lead, Arikace consistently caught up to practically dead even, proving sustained efficacy that matched the phase 2 results. Tobi is not a bad antibiotic as many have portrayed it, but Arikace achieved sustained efficacy with good safety with a far great ease of use (once daily vs. twice). This is why I initially stated that Arikace kicked Tobi's butt. As for the minutia that some health experts are tripping over, it's the achievement of non-inferiority that really counts. Doctors vouched for the viablity and efficicacy on the conference call, which I listened to live. Every analyst is on board and there will be more to come. Folks, we have a winner!!!
God bless the USA!